Note 1 - Nature of Business and Significant Accounting Policies (Details)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
|
|
|
|
|
Jun. 24, 2019
USD ($)
|
Feb. 04, 2019
USD ($)
|
Jan. 29, 2019
USD ($)
|
Oct. 31, 2018
USD ($)
|
Jul. 03, 2018
USD ($)
|
Jun. 27, 2018
USD ($)
shares
|
Jun. 01, 2018
USD ($)
$ / shares
|
Feb. 28, 2018
USD ($)
|
Feb. 05, 2018
USD ($)
|
Dec. 04, 2017
USD ($)
|
Apr. 29, 2015
shares
|
Dec. 10, 2014
shares
|
Nov. 12, 2014
shares
|
Aug. 31, 2019
USD ($)
shares
|
Aug. 31, 2018
USD ($)
$ / shares
shares
|
May 31, 2019
USD ($)
|
May 31, 2018
USD ($)
|
Jun. 20, 2017
$ / shares
|
May 31, 2017
$ / shares
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions |
|
|
|
|
|
|
|
10.00%
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
| Financing Receivable, after Allowance for Credit Loss, Current |
|
|
|
$ 5,000,000
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
$ 1,275,411
|
|
$ 850,958
|
|
|
|
| Note Receivable, Interest Rate, Stated Percentage |
|
|
|
6.00%
|
6.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Acquire Notes Receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
175,000
|
$ 0
|
|
|
|
|
| Cash and Cash Equivalents, at Carrying Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
5,907,899
|
5,953,925
|
$ 10,525,791
|
$ 52,964
|
|
|
| Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| Advertising Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
205,978
|
$ 0
|
|
|
|
|
| Research and Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
| Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.25
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
86,452,881
|
87,162,289
|
|
|
|
|
| Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt |
|
|
|
|
|
|
$ 1,265,751
|
|
|
|
|
|
|
$ 0
|
$ 1,265,751
|
|
|
|
|
| Embedded Derivative Financial Instruments [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price (in Dollars per share) | $ / shares |
|
|
|
|
|
|
$ 0.6865
|
|
|
|
|
|
|
|
|
|
|
$ 0.710
|
|
| Debt Instrument, Convertible, Terms of Conversion Feature |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
That the conversion price of the YAN II PN Convertible Notes would be equal to $0.40 with a full reset feature, and upon default, 75% of the lowest Variable Weighted Average Price (“VWAP”) in the 15 consecutive trading days ending on the trading day that is immediately prior to the applicable conversion date
|
|
|
|
|
| Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.40
|
|
|
|
|
| Event of Default, Decription |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
That an event of default at 24% or 15% interest rate would occur 0% of the time, increasing 1.00% per month to a maximum of 25%, and that instead of a penalty, there would be an alternative conversion price
|
|
|
|
|
| Note Redemption, Projection |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
That the Company would redeem the convertible notes, projected initially at 0% of the time and increasing monthly by 1.0% to a maximum of 10.0% (from alternative financing)
|
|
|
|
|
| Joint Venture with CannAssist [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Line of Credit Facility, Description |
|
|
Any draws on the line of credit in excess of $150,000 will only be made in the sole discretion of the Company.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
8.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Acquire Notes Receivable |
$ 175,000
|
$ 150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Financing Receivable, after Allowance for Credit Loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
325,000
|
|
|
|
|
|
| Interest Receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,564
|
|
|
|
|
|
| Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
54,835,145
|
21,139,000
|
|
|
|
|
| Unite Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
7,676,974
|
4,635,684
|
|
|
|
|
| Convertible Debt Securities [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
23,704,094
|
3,245,858
|
|
|
|
|
| Stock Payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
236,668
|
195,709
|
|
|
|
|
| Special Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57,946,038
|
|
|
|
|
| Measurement Input, Default Rate [Member] | Embedded Derivative Financial Instruments [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Embedded Derivative Asset (Liability) Net, Measurement Input |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.24
|
|
|
|
|
| Measurement Input, Default Rate [Member] | Embedded Derivative Financial Instruments [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Embedded Derivative Asset (Liability) Net, Measurement Input |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.15
|
|
|
|
|
| Measurement Input, Price Volatility [Member] | Embedded Derivative Financial Instruments [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Embedded Derivative Asset (Liability) Net, Measurement Input |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.428
|
|
|
|
|
| Measurement Input, Price Volatility [Member] | Embedded Derivative Financial Instruments [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Embedded Derivative Asset (Liability) Net, Measurement Input |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.974
|
|
|
|
|
| Reverse Merger with CLS Labs [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
15,000,000
|
|
|
|
|
|
|
|
|
| Oasis Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Acquire Businesses, Gross |
|
|
|
|
|
$ 2,050,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Liabilities Assumed |
|
|
|
|
|
204,457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Consideration Transferred |
|
|
|
|
|
27,975,650
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Consideration Transferred, Liabilities Incurred |
|
|
|
|
|
3,810,820
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oasis Acquisition [Member] | Oasis LLCs [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Acquire Businesses, Gross |
|
|
|
|
$ 6,200,000
|
$ 5,995,543
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |
|
|
|
|
|
90.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
$ 4,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares) | shares |
|
|
|
|
|
22,058,823
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Liabilities Assumed |
|
|
|
|
204,457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| In Good Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Acquire Businesses, Gross |
|
|
|
|
35,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Consideration Transferred |
|
|
|
|
47,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Consideration Transferred, Liabilities Incurred |
|
|
|
|
7,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Issued in Business Combination, Fair Value Disclosure |
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Consideration Transferred, Other |
|
|
|
|
2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Option Agreement, Brake-Up Fee |
|
|
|
$ 2,500,000
|
$ 2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deposit [Member] | Oasis Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Acquire Businesses, Gross |
|
|
|
|
|
|
|
|
|
$ 250,000
|
|
|
|
|
|
|
|
|
|
| Additional Payments [Member] | Oasis Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Acquire Businesses, Gross |
|
|
|
|
|
|
|
$ 1,800,000
|
$ 1,800,000
|
|
|
|
|
|
|
|
|
|
|
| CLS Labs, Inc. [Member] | Shares of CLS Holdings USA, Inc. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
6,250,000
|
10,000,000
|
|
|
|
|
|
|
| Equity Method Investment, Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
55.60%
|
|
|
|
|
|
|